Real-World Effectiveness and Risk Factors for Discontinuation of Ustekinumab in Ulcerative Colitis

Real-World Effectiveness and Risk Factors for Discontinuation of Ustekinumab in Ulcerative Colitis

Introduction: Ustekinumab (UST) has been approved for the treatment of moderate-to-severe ulcerative colitis (UC). Real-world data showing the effectiveness and safety of UST are necessary to confirm the results of clinical trials for applicability in daily clinical practice. Although some studies h...

Full description

Bibliographic Details
Main Authors: Genta Uchida, Masanao Nakamura, Takeshi Yamamura, Keiko Maeda, Tsunaki Sawada, Eri Ishikawa, Kazuhiro Furukawa, Tadashi Iida, Yasuyuki Mizutani, Kentaro Yamao, Takuya Ishikawa, Yoji Ishizu, Takashi Honda, Masatoshi Ishigami, Hiroki Kawashima
Format: Article
Language:English
Published: Karger Publishers 2023-06-01
Series:Inflammatory Intestinal Diseases
Subjects:
real-world evidence
ustekinumab
ulcerative colitis
effectiveness
risk factor
Online Access:https://beta.karger.com/Article/FullText/531497

Internet

https://beta.karger.com/Article/FullText/531497

Similar Items